Overview
- ART27.13 helped patients gain an average 6.4% of body weight over 12 weeks versus a 5.4% loss on placebo in a double-blind phase 2 study.
- The trial enrolled 25 people with advanced cancers across tumor types, and investigators reported no notable side effects or psychoactive effects.
- Wearable data indicated increased physical activity among treated patients, while activity declined in the placebo group.
- Artelo Biosciences plans a phase 3 program roughly 12 times larger before seeking MHRA and international regulatory reviews.
- The company says the drug could reach patients as early as 2028 if larger trials confirm efficacy and safety and regulators approve it.